Market News & Analysis

Credible tests dig a deeper hole for RBS

The Bank of England’s stress tests may not have proved much, but they did show that RBS shares could still crater more, even after losing more than 30% for the year by Tuesday night.


Of Britain’s other lenders, only Lloyds could be said to have passed with something like flying colours, but only Royal Bank of Scotland flunked across the board.

RBS’s battered stock fell as much as 5% on Wednesday morning, before halving the amount later.

The move probably tells us as much about price momentum as it shines a light on sentiment among the public-owned group’s private investors.

Still, although it is unlikely that many of them will have many illusions left about RBS’s ability to strengthen returns sustainably anytime soon, its inability to meet this year’s stressed 7.3% core capital target whilst StanChart, Barclays, HSBC and Lloyds were, is an eye opener for investors.

The 71.5% state-owned group was not even able to match the government’s buffer after triggering an emergency conversion of contingent convertible (CoCos) bonds into equity, the very purpose for which the paper was made eligible as regulatory capital.


The outcome should also, unfortunately, prick the illusion that reported capital ratios offer reliable insight into a bank’s ability to withstand economic or financial shocks.

RBS notably posted the highest core capital amongst its rivals in 2015 at 15.5%.

Admittedly, the BoE went to town with its stress scenario this time, demanding a minimum T1 capital ratio of 4.5%, envisaging a property price rout and a global economic collapse, replete with $20/bbl. oil.

Bank-specific risks tightened conditions further, case-by-case.

Barclays and particularly commodities-dependent StanChart only got over the wall after dividend freezes and CoCo conversions.

HSBC and Lloyds limped, seeing core equity compressed to 7.6% and 9.7% from 11.9% and 12.8% respectively, but would not have imploded.

After RBS’s capital cushion only reached 5.5%, it last night rushed out a statement pledging to raise about £2bn in a new agreed capital plan with the BoE. That requires deeper cost cuts, more balance sheet lightening and non-core asset liquidations.

Raising credible bank capital in a world of collapsed bank capital values is not going to be smooth, but at least the prospect of state embarrassment from another government cash injection looks to have been avoided.

However, expectations for RBS were already dire, and logically, there is now room for forecast downgrades. Thomson Reuters data shows investors see its return on equity at 2.7% this fiscal year, a positive figure compared with negative returns at the end of 2015 albeit well below expectations of 10.4% for Lloyds and 10.9% at upstart rival Virgin Money. One failed stress test later, any hope that the RBS’s stock and financial strength had reached a floor needs to be dropped.

On a more positive note, Britain’s bank testing regime itself was on trial as much as its lenders.

The weakest bank was indeed ‘busted’ and market views of which UK-facing banks were stronger were corroborated. Compare those outcomes with ECB stress tests during the summer, which had no clear pass and fail.

Investors in Barclays, Lloyds and HSBC still need to tread carefully through a hazard strewn outlook.  But now, there are fewer reasons to look in RBS’s direction.



Please click image to enlarge


The technical chart of RBS stock shows prices have today broken back below an unequivocal falling trend that definitively recommenced in June last year.

Following its recovery from post-Brexit-vote lows, there were even hopes that the shares had gathered sufficient momentum to follow through.

It has however been clear since the middle of the month that that wasn’t going to happen. The (re)break down beneath the trend looks set to seal this year’s sell-off at prices close to the worst.

The best outcome that investors might hope for is that support established around 170p will hold, thereby avoiding another visit to 7-year lows seen in July just under 150p.



More From Ken Odeluga

From time to time, GAIN Capital Limited’s (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.

As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.